Endogenous cannabinoids in amygdala and hippocampus in post-mortem brains of Cloninger type 1 and 2 alcoholics

Kärkkäinen, Olli K

Elsevier BV

info:eu-repo/semantics/acceptedVersion
© Elsevier Inc.
CC BY-NC-ND https://creativecommons.org/licenses/by-nc-nd/4.0/
http://dx.doi.org/10.1016/j.alcohol.2013.05.003

https://erepo.uef.fi/handle/123456789/5220
Downloaded from University of Eastern Finland's eRepository
Endogenous cannabinoids in amygdala and hippocampus in post-mortem brains of Cloninger type 1 and 2 alcoholics

Olli K. Kärkkäinen a, b;
Marko Lehtonen c;
Virpi Laukkanen a, b;
Erkki Tupala b, †;
Petri Hytyiä e;
Hannu Kautiainen f, g;
Jari Tiihonen b, h;
J.C. Callaway d;
Markus Storvik a, *

a Pharmacology and Toxicology, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
b Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, FI-70240 Kuopio, Finland
c Pharmaceutical Chemistry, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
d Biocenter Kuopio, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
e Institute of Biomedicine, University of Helsinki, P.O. Box 63, 00014 University of Helsinki, Finland
f Unit of Family Practice, Central Finland Central Hospital, Jyväskylä, Finland
g Unit of Primary Health Care, Kuopio University Hospital, Finland
h Department of Clinical Neuroscience, Karolinska Institutet, SE-171 77 Stockholm, Sweden

† Deceased

* Corresponding author: Markus Storvik, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland; Phone: +358-40-5110 223; FAX: +358-17-162 424; E-mail: markus.storvik@uef.fi
Abstract

Accumulating evidence continues to link certain aspects of the endogenous cannabinoid (EC) system with alcohol dependence, negative reinforcement learning and the modulation of stress response. Specific alterations in brain regions that are related to stress and negative reinforcement learning have been reported to exist in Cloninger type 1 and 2 alcoholics. To study possible differences in profiles of ECs between Cloninger type 1 (n=9), type 2 (n=8) alcoholics and non-alcoholic control subjects (n=10), we analyzed post-mortem amygdala and hippocampus brain samples for several ECs by quantitative liquid chromatography with triple quadrupole mass spectrometric detection. A significant difference was found between these three groups in terms of EC profiles in the amygdala (p = 0.037). In particular, this difference was prominent for variations in docosahexaenoylthanolamine levels, which were significantly higher in type 1 alcoholics (p = 0.022) when compared to controls. There was also a large negative correlation between anandamide concentration and mGlu1/5 receptor density in the hippocampus of Cloninger type 1 alcoholics (R=-0.88, p=0.002), which was not seen in type 2 alcoholics or in controls. Although preliminary, and from relatively small diagnostic groups, these results suggest that the EC profile may be altered in the hippocampus and amygdala of type 1 alcoholics.

Keywords

Endocannabinoids; Anandamide; 2-Arachidonoylglycerol; Docosahexaenoylthanolamide; Late onset alcoholism
Introduction

Alcoholism has become the most harmful drug of abuse, especially when harm to the alcoholic individual and society are taken into account (Nutt et al., 2010). Moreover, alcohol consumption is one of the leading risk factors of death among the working age population (World Health Organization, 2011). Alcoholics are a heterogeneous group with a wide spectrum of emotional, social and medical problems. In Cloninger’s typology, alcoholics are divided into two groups (Cloninger, 1995); type 1 alcoholics who are anxiety prone and characterized by adult onset alcoholism, and type 2 alcoholics who are characterized by impulsive, antisocial behavior and teenage onset alcoholism. We previously reported on decreased dopamine function in post-mortem brains of Cloninger type 1 alcoholics (Tupala et al., 2000; Tupala et al., 2001; Tupala and Tiihonen, 2004) and alterations in the serotonergic signaling in both type 1 and type 2 alcoholics (Leggio and Addolorato, 2008; Mantere et al., 2002; Storvik et al., 2006; Storvik et al., 2009).

The behavioral characteristics seen in type 1 and type 2 alcoholics suggest that both groups may have problems in modulating appropriate stress responses (Cloninger, 1995). Dysfunctional stress responses, including allostatic alterations in the function of the stress-mediating amygdala and stress-inhibiting hippocampus, have been hypothesized to be one of the key neural changes in the pathology of addiction, which proceeds from a negative reinforcement of learning processes (Funk et al., 2006; Koob and Le Moal, 2008; Vendruscolo et al., 2012). Alterations in the stress systems of Cloninger type 1 and type 2 alcoholics have been reported, for example, as altered metabotropic glutamate receptor 1/5 (mGluR1/5) densities in the hippocampus (Kupila et al., 2012), altered serotonin transporter (SERT) densities in the amygdala (Storvik et al., 2007) and altered ratios between SERT densities in the amygdala and hypothalamus (Storvik et al., 2008).
Endocannabinoids (ECs) have been associated with alcohol dependence (Pava and Woodward, 2012), with the regulation of stress response (Ruehle et al., 2012) and with the modulation of stress-enhanced negative reinforcement learning (Campolongo et al., 2009; Ramot and Akirav, 2012). ECs have both anxiogenic and anxiolytic properties, and this biphasic response has been suggested to result from changes in cannabinoid receptor type 1 (CB1) expression in both glutamatergic and GABAergic axon terminals (Millan, 2003). Furthermore, different brain regions seem to be responsible for the anxiogenic and anxiolytic properties of ECs (Rubino et al., 2008a). It has also been suggested that ECs can activate other receptors, such as the transient receptor potential vanilloid 1 (TRPV1), which may contribute to anxiogenic effects (Rubino et al., 2008b). Recently, we reported on significantly altered endocannabinoid levels in the Cloninger type 1 nucleus accumbens, cingulate cortex and frontal cortex (Lehtonen et al., 2010).

To our knowledge, EC profiles in the amygdala and hippocampus of Cloninger type 1 and 2 alcoholics have not been previously reported. The main aim of the present study was to examine endocannabinoid profiles in the amygdala and hippocampus by measuring 2-arachidonoyl glycerol (2-AG), arachidonylethanolamine (anandamide, AEA), dihomo-γ-linolenylethanolamine (LEA), docosatetraenylethanolamine (DHEA), palmitoyl ethanolamine (PEA) and oleoyl ethanolamine (OEA) levels in post-mortem brain samples of type 1 and 2 alcoholics and a control group. Secondary aim of the present study was to determine possible correlations between EC levels and previously published mGluR1/5 densities from these same individuals (Kupila et al., 2012), because activation of mGluR5 has been associated with the release of ECs (Chavez et al., 2010).
Materials and methods

Study subjects, sampling and diagnostics

The selection and collection of post-mortem human brains, psychological diagnostics and sample preservation methods have already been described in detail (Mantere et al., 2002; Tupala et al., 2001). Briefly, left hemispheres were obtained during clinical necropsy at the Department of Forensic Medicine, University of Oulu, Finland, and the Department of Forensic Medicine, University of Kuopio, Finland. The Ethics Committee of the University of Oulu and the National Institute of Medico-legal Affairs, Helsinki, Finland, approved the study. The brains were removed, cleaned of the dura, and divided at the midsagittal plane. The left hemisphere was placed with the midsagittal plane on a glass plate before freezing at −75 °C. None of the hemispheres exhibited damage or neuroanatomical abnormalities. Brain sample were Cryosectioned into 100-µm horizontal (cantomeatal) slices (Tupala et al., 2001). Theses sections were allowed to air dry before they were stored with dehydrating agents at −25 °C until use.

Medical records on the cause of death, previous diseases and medical treatments were collected. Alcoholism was coded according to DSM-IV criteria (APA, 1994), and sub-classified as type 1 or 2, according to Cloninger’s typology of alcoholism (1995). Two physicians reviewed medical records and anamnestic data, which included extant criminal records. The two main criteria for defining type 2 alcoholics were early onset of alcohol abuse (i.e., before the age of 25) and a record of severe antisocial behavior. The Cohen's kappa coefficient of diagnostic agreement subjects was 0.9; i.e., one of the type 2 alcoholics was diagnosed as a type 1 alcoholic by the second physician. Otherwise, diagnoses were unanimous. Subjects with psychotic disorders or any neurological diseases, or those taking medication that could affect the CNS (such as neuroleptics or antidepressants), or the use of
substances that directly affect the dopaminergic system (e.g., psychostimulants or opioids) were excluded.

The study groups consisted of 17 alcoholics that were further sub-classified as type 1 alcoholics (N=9, seven males, two females; mean age 52.7 years; post-mortem interval (PMI) 11.9 ± 4.5 h; mean ± SD), and type 2 alcoholics (N=8, all males; mean age 34.6 years; PMI 14.1 ± 3.4 h; mean ± SD). The control group consisted of 10 non-alcoholic subjects (eight males, two females; mean age 53.5 years; PMI 14.8 ± 9.2 h; mean ± SD) who were free of psychiatric diagnosis. All subjects died of sudden causes, and individual data are shown in Table 1. Alcoholism was determined by frequent admissions to emergency stations and other medical appointments due to alcohol-related problems. Eight of the nine type 1 alcoholics had ethanol in their blood at their time of death, and one had an abstinence period of 10 h while incarcerated. One of the controls had a small amount of ethanol in his blood at the time of death (0.36‰ blood alcohol content). Two of the type 1 alcoholics had traces of diazepam in their blood samples. Six type 2 alcoholics had ethanol in their blood at the time of death, and three had traces of benzodiazepines. One type 2 alcoholic had an abstinence period of five days and another abstained for three to seven days. Mean blood alcohol concentration (BAC) was 2.0 ± 1.7‰ and 1.9 ± 1.4‰ for the type 1 and 2 alcoholics at the time of death, respectively, and these two groups did not differ in this regard [F(0.174), p = 0.90, independent samples t-test](Tupala et al., 2008). Evaluations for the duration of heavy alcohol use, family histories of alcohol misuse and tobacco smoking, based on medical records, were considered to be unreliable and thus not considered in the final analysis.
Post-mortem brain EC levels were measured from amygdala and hippocampus by a liquid chromatography/tandem mass spectrometric (LC/MS/MS) method (Lehtonen et al., 2011). Briefly, frozen post-mortem brain tissues (1–3 mg) were removed from the glass slide with a scalpel and transferred to a pre-weighed Eppendorf tube, then weighed again to determine the precise amount of sample. Methanol (500 µl) and the deuterated internal standards AEA-d8 (50 µl, 50 nM) and 2-AG-d8 (50 µl, 460 nM) were added to the sample and homogenized with ultrasonification. Lipids were extracted by adding chloroform and water to yield a final methanol/chloroform/water ratio of 1:2:1 (v/v/v), then centrifuged at 1500 × g for 10 min at 10 °C. The upper aqueous layer was discarded and the lower organic layer was transferred to a screw capped glass test tube. The liquid extraction was repeated, the chloroform phases were combined and then evaporated to dryness under nitrogen at 20 °C. The residue was reconstituted in 70 µl of an ice-cold acetonitrile water solution (5:2, v/v). The sample was then transferred to a sample vial for the separation of ECs by liquid chromatography (Agilent 1200 Series Rapid Resolution LC System, Agilent Technologies, Waldbronn, Germany), and measured by electrospray ionization (ESI) triple quadrupole mass spectrometric detection (Agilent 6410 Triple Quadrupole LC/MS, Agilent Technologies, Palo Alto, CA, USA). For each analysis, 10 µl of sample solution was injected onto a reversed phase HPLC column (Zorbax Eclipse XDB-C18 Rapid Resolution HT 2.1 × 50 mm, 1.8 µm) (Agilent Technologies, Palo Alto, CA, USA) using an isocratic mobile phase that consisted of 67% of 0.1% formic acid in acetonitrile and 33% of 0.1% formic acid in water. Ionization was performed with positive ESI and detection was by multiple reaction monitoring (MRM). This analytical method was selective, accurate and precise for concentrations within a calibration range of 0.4–40 nM for N-acylethanolamines (NAEs: i.e., AEA, DHEA, LEA, PEA, and OEA) and 40–5000 nM for 2-AG.
The measured concentrations of individual endocannabinoids were standardized to same mean and distribution within variable and across the study groups by standard deviation. The results are expressed as standardized values to enable comparison of EC profiles for six different ECs between the groups. Statistical significance of the differences in the EC concentrations between the three groups were evaluated by permutation type multivariate test of variance (MANCOVA). The PMI was used as a covariate because it has an effect on brain EC concentrations (Palkovits et al., 2008) and because it was observed that within the present data there was moderate correlation between EC concentrations and PMI (Pearson correlation). The 95% confidence intervals for the most important outcomes were obtained by bias-corrected bootstrapping (5,000 replications).

In order to study the possible correlations of measured EC levels to the regulatory mGlu1/5 receptor system, Spearman correlations were calculated to determine direct correlations of EC levels to previously published mGlu1/5 receptor densities (Kupila et al., 2012). The differences in Spearman correlations between the subject groups were tested by Fisher’s (z)-transformation of correlations to evaluate the overall differences, followed by a Tukey-type test to compare individual groups. Correlations greater than 0.5 were considered to be large (Cohen, 1988). STATA (release 11.2, College Station TX) was used for all statistical analyses.
Results

The LC/MS/MS method was able to quantify the four most common ECs (i.e., 2-AG, AEA, LEA, and DHEA) and two other cannabimimetic compounds (PEA and OEA) in the amygdala and hippocampus of all subjects. The quantitative amounts of measured compounds were specific for both the brain regions and the subject groups. 2-AG was the most abundant EC found in both studied brain regions of all groups. The results of measured endocannabinoid profiles are presented in Figure 1 and in Supplementary table 1.

There was a significant difference in the endocannabinoid profiles between the three groups in the amygdala (p = 0.037, Figure 1). Further, this difference in the amygdala endocannabinoid profiles was especially prominent for DHEA between type 1 alcoholics and the control group (p = 0.022), with the type 1 alcoholics showing significantly higher DHEA levels. There were no significant differences in hippocampal endocannabinoid profiles between the three groups (p = 0.21, Figure 1).

There was a large negative correlation between AEA levels in hippocampus and previously published mGluR1/5 receptor concentrations (Kupila et al., 2012) in the hippocampal CA1 region (R=-0.88; Figure 2) in Cloninger type 1 alcoholics. This correlation was not seen in the control group or in type 2 alcoholics, and the difference between the three study groups was significant ($\chi^2=9.403$, p=0.009). Because of the limitations in the sampling method, we were not able to measure EC levels from only the CA1 region of the hippocampus.
Discussion

In this study, EC levels were measured in the amygdala and hippocampus of Cloninger type 1 and 2 alcoholic post-mortem brains, and compared with analogous samples from a group of non-alcoholic controls. A statistically significant (p=0.037) difference in EC profiles between the groups was found in the amygdala (Figure 1). In the hippocampus, there were no significant differences in the EC profiles between the groups. The main difference in the amygdala EC profiles was localized to DHEA levels, where type 1 alcoholics had increased DHEA levels when compared to the control group. The Cohen’s effect size for this finding was large (-0.98), which increases the validity of this result, despite the p-value being only 0.022.

DHEA is an ethanolamide derivative of the omega-3 fatty acid docosahexaenoic acid (DHA), and in the context of addiction, low plasma levels of DHA have been associated with increased relapse vulnerability (Buydens-Branchey et al., 2009). DHEA is referred as an endocannabinoid, even though it has only a weak affinity to cannabinoid receptors (Felder et al., 1993). Therefore, it is possible that DHEA has still unknown primary target molecule. Current knowledge on the role of DHEA in the central nervous system, especially in the amygdala, is limited. DHEA has been found to promote synaptic development and glutamatergic synaptic activity in hippocampal neurons (Kim et al., 2011a; Kim et al., 2011b). DHEA oxidative metabolism products have also been associated with anti-inflammatory and neuroprotective properties (Yang et al., 2011). Increased levels of DHEA in the amygdala could be associated with anxiety-prone behavior seen in type 1 alcoholics, but before future research clarifies the role of DHEA in the amygdala no valid conclusion can be made.

In the present study, a large negative correlation between AEA levels in the hippocampus and previously published mGluR1/5 densities in the CA1 hippocampal region (Kupila et al., 2012) of
Consumption of alcohol has been associated with alterations in 2-AG and AEA levels in both amygdala and hippocampus (Gonzalez et al., 2004; Malinen et al., 2009; Rubio et al., 2007). However, in the present study the differences in the EC profiles were not localized to these two endocannabinoids and altered correlation between EC levels and previously published mGluR1/5 densities was only seen in the hippocampal AEA levels. In a previous human post-mortem brain study, differences were only found in AEA levels of cortical regions and the NAc (Lehtonen et al., 2010). Together, these findings suggest that in human alcoholism the changes in 2-AG may not be as important as suggested from animal models (Gonzalez et al., 2004; Lehtonen et al., 2010; Malinen et al., 2009; Rubio et al., 2007).

In the present study, we included PMI as a covariant to minimize its influence on the results, because it has an effect to the EC levels in post-mortem brain samples and that this effect is EC specific (Palkovits et al., 2008). There were moderate correlations between PMI and EC levels in the present data (Supplementary Figures 1 and 2) further justifying the use of PMI as a covariant.
the present study, like all post-mortem studies, is that the EC levels from post-mortem samples might not fully represent the levels prior to death. Therefore, future research is needed to verify the present results in vivo and to examine EC binding sites, e.g. CB1 and TRPV1, in alcoholics.

Although the results from the present study are preliminary, and from diagnostic groups with a relatively small number of subjects, these findings reveal interesting alterations in the post-mortem brain profiles of ECs for Cloninger type 1 and 2 alcoholics. Our results show increased levels of DHEA in the amygdala and a large negative correlation between AEA and previously published mGluR1/5 densities (Kupila et al., 2012) in the hippocampus of type 1 alcoholics. Together, with previous findings of altered function of the amygdala and hippocampus (Kupila et al., 2012; Storvik et al., 2007; Storvik et al., 2008), these results suggest that altered function of the stress system might enforce the typical behavioural patterns seen in the anxiety-prone type 1 alcoholics. Further study is needed to clarify the role of stress systems and ECs in the pathology of alcoholism.
Acknowledgements

The highly competent technical help of Ms. Anne Kaikko in the analytical laboratory and Ms. Aija Räsänen for dedicated secretarial services are highly appreciated. This study was supported by funding from the Annual EVO financing (a special government subsidy from the Finnish Ministry of Health and Welfare). The researchers were independent of the funder, which had no role in the study design its execution, or in the preparation of this report or the decision to submit the paper for publication.
Reference List


Figure 1. Amygdala and hippocampus endocannabinoid profiles of the nonalcoholic control group, with Cloninger type 1 and type 2 alcoholics.

Amygdala (A) and Hippocampus (B) endocannabinoid profiles of the control group, type 1 and type 2 alcoholics presented as standardised values with 95% confidence intervals. In the amygdala there was a significant difference in the EC profiles between the groups (p=0.037). The main difference between the EC profiles was localised to DHEA concentrations between type 1 alcoholics and the controls (p=0.022). In hippocampus there were no statistically significant differences between the groups (p=0.21). EC, endocannabinoid; 2-AG, 2-arachidonoyl glycerol; AEA, arachidonoylethanolamine ; LEA, dihomo-γ-linolenoylethanolamine; DHEA, docosahexaenoylethanolamine; OEA, oleoyl ethanolamine; PEA, palmitoyl ethanolamine; *, p<0.05.
Figure 2. Spearman correlations between hippocampal AEA levels and previously published mGluR1/5 densities in the hippocampal CA1 region.

Type specific correlations can be seen between type 1, type 2 and controls in correlations between AEA levels and previously published mGluR1/5 densities (Kupila et al., 2012). AEA, arachidonoylethanolamine (anandamide); Hipp, hippocampus; mGluR1/5, metabotropic glutamate receptor 1/5; CA1, CA1 regions of hippocampus.
**Suplementary Figure 1.** Pearson correlations between hippocampal AEA levels and post-mortem interval values.

Type specific correlations can be seen between type 1, type 2 and controls in correlations between AEA levels and post-mortem interval values.

AEA, arachidonoylethanolamine (anandamide); Hipp, hippocampus; PMI, post-mortem interval.

**Suplementary Figure 2.** Pearson correlations between DHEA levels in amygdala and post-mortem interval values.

Type specific correlations can be seen between type 1, type 2 and controls in correlations between DHEA levels and post-mortem interval values.

Amy, amygdala; DHEA, docosatetraenoylethanolamine; PMI, post-mortem interval.